NUVL
Nuvalent, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Nuvalent, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
No changes.
No changes.
Last report1 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
−1.78%
vs ±5.1% implied · ×0.35
shaded = implied · ▲▼ = realized
Nuvalent, Inc.
123.96
+0.02 · +0.02%
post 123.96 0.00%
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Deerfield | $2.1B | 22.28% | 0.00% |
| Paradigm Biocapital | $731.7M | 7.65% | +11.27% |
| BlackRockindex-like | $689.8M | 7.22% | +15.77% |
| HBK Investments L P | $430.2M | 4.50% | new |
| FIL | $363.9M | 3.81% | +4532986.15% |
| Manager | Value | % base | |
|---|---|---|---|
| Deerfield | $2.1B | 22.28% | 0.00% |
| Paradigm Biocapital | $731.7M | 7.65% | +11.27% |
| BlackRockindex-like | $689.8M | 7.22% | +15.77% |
| HBK Investments L P | $430.2M | 4.50% | new |
| FIL | $363.9M | 3.81% | +4532986.15% |
Largest filed tie
0
filed ties
Bull2
Bear1
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Nuvalent, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Nuvalent, Inc.'s 6 closest co-movers, none share that code.
Expected move
No implied move.